GeminIQ Website Logo

Viewing DMII free

Subscribe for full history, 50+ metrics, screener, watchlist...

Drugs Made In America Acquisition II Corp.

DMII

Companies in Blank Checks

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Sponsor
--1
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
0--
Cash
000
Prepaid Expense Current
000
Assets Current
001
Assets Noncurrent
Assets Held In Trust Noncurrent
509505500
Assets Noncurrent
509505-
Assets
510505501
Liabilities And Stockhold…
Liabilities Current
Other Liabilities Current
-01
Accounts Payable Current
000
Accrued Liabilities Current
000
Notes Payable Current
0--
Liabilities Current
101
Liabilities Noncurrent
Liabilities Noncurrent
1818-
Liabilities
181818
Temporary Equity Carrying Amount Attributable To P…
509505500
Stockholders Equity
Common Stock Value
000
Retained Earnings Accumulated Deficit
-18-18-17
Stockholders Equity
-18-18-17
Liabilities And Stockholders Equity
510505501
Over Allotment Option
-0-
Common Stock
-14-
Allowance For Doubtful Accounts Receivable Current
11-
Temporary Equity Shares Outstanding
505050
Temporary Equity Redemption Price Per Share
10.1910.110
Preferred Stock Shares Authorized
111
Preferred Stock Par Or Stated Value Per Share
000
Common Stock Par Or Stated Value Per Share
000
Common Stock Shares Authorized
220220220
Common Stock Shares Issued
141416
Shares Outstanding
141416

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
20260.50%0.60%----
2025---0.10%0.80%0.90%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
0.53
0.09
1.32
Quick Ratio
0.52
0.00
1.30
Working Capital
-314.52K
-274.83K
219.01K
Leverage & Debt
Debt to Equity
-1.02
-1.00
-1.05
Debt Ratio
0.04
0.04
0.04
Valuation Metrics
P/B TTM
-27.98
-29.60
-
Market Cap
498.50M
526.19M
-
Enterprise Value
498.60M
526.19M
-
Calculated Values
Net Debt
102.28K
-223.00
-315.09K
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2025-09-26Purchase
Owner: Drugs, Made In America Ac…
Title: -
Shares: 700,000
Price/Share: -
Value: -
Shares Owned: 15,075,000
Relationship: TenPercentOwner
Ownership: Direct
2025-09-26Purchase
Owner: Stockwell, Lynn
Title: CEO and Exe. Chair of Board
Shares: 700,000
Price/Share: -
Value: -
Shares Owned: 15,075,000
Relationship: Director,Officer,TenPercentOwner
Ownership: Indirect
2025-09-26Sale
Owner: Drugs, Made In America Ac…
Title: -
Shares: 7,966,667
Price/Share: -
Value: -
Shares Owned: 6,708,333
Relationship: TenPercentOwner
Ownership: Direct
2025-09-26Sale
Owner: Stockwell, Lynn
Title: CEO and Exe. Chair of Board
Shares: 7,966,667
Price/Share: -
Value: -
Shares Owned: 6,708,333
Relationship: Director,Officer,TenPercentOwner
Ownership: Indirect

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2025-12-31
58.23%
Inst. Shares: 30,951,671
Shares Outstanding: 53,150,684

Drugs Made In America Acquisition II Corp. (DMII) — SEC Financial Statements & Analysis

Drugs Made In America Acquisition II Corp. (DMII) is a blank checks company. Drugs Made In America Acquisition II Corp. trades on DMIIU: Nasdaq as: DMII: Nasdaq, DMIIR: Nasdaq. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Drugs Made In America Acquisition II Corp. reported a Debt-to-Equity ratio of -1.02x, a Price-to-Book (P/B) ratio of -27.98 (TTM), at a market cap of $498.50M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity
-1.02x
P/B TTM
-27.98
Market Cap
$498.50M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Drugs Made In America Acquisition II Corp. in?

Drugs Made In America Acquisition II Corp. (DMII) operates in the Blank Checks industry.

What is DMII's market cap?

Drugs Made In America Acquisition II Corp. (DMII) has a market capitalization of $498.50M as of 2026-03-31.

What exchange does DMII trade on?

Drugs Made In America Acquisition II Corp. (DMII) trades on the DMIIU: Nasdaq.

Research Faster.
Invest Smarter.

Drugs Made In America Acquisition II Corp. (DMII) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 50+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.